Vir Biotechnology (VIR) Gains from Sales and Divestitures (2018 - 2022)

Vir Biotechnology's Gains from Sales and Divestitures history runs 5 years deep, the most recent figure standing at $349496.0 for Q4 2022.

• In Q4 2022, Gains from Sales and Divestitures changed N/A year-over-year to $349496.0; the TTM figure through Dec 2022 stood at $349496.0 (changed N/A YoY), while the FY2022 annual figure was $349496.0, changed N/A from the prior year.
• Gains from Sales and Divestitures came in at $349496.0 for Q4 2022 at Vir Biotechnology, up from $216886.0 in the prior quarter.
• In the past five years, Gains from Sales and Divestitures ranged from a high of $2.2 million in Q4 2018 to a low of $52963.0 in Q1 2021.
• A 5-year average of $1.1 million and a median of $924352.0 in 2020 frame the typical range for Gains from Sales and Divestitures.
• Across the five-year window, Gains from Sales and Divestitures tumbled 95.02% in 2021 and jumped 309.5% in 2022, its largest moves.
• Vir Biotechnology's Gains from Sales and Divestitures stood at $2.2 million in 2018, then declined by 11.63% to $2.0 million in 2019, then slipped by 9.79% to $1.8 million in 2020, then sank by 95.02% to $89261.0 in 2021, then surged by 291.54% to $349496.0 in 2022.
• According to Business Quant data, Gains from Sales and Divestitures over the past three periods registered $349496.0, $216886.0, and $89261.0 for Q4 2022, Q1 2022, and Q3 2021 respectively.

Peer Comparison